arrow
R

Ricardo Machado Xavier

Hospital de Clínicas de Porto Alegre
H指数:45
被引数:9,411

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Validity of Bioelectrical Impedance Analysis for the Assessment of Body Composition in Patients With Systemic Sclerosis

生物电阻抗分析在系统性硬化病患者体成分评估中的有效性

2026-03-260
OAAI
Position statement of the Biotechnology Committee of the Brazilian Society of Rheumatology on the interchangeability of originator and biosimilar biologics in immune-mediated rheumatic diseases

巴西风湿病学学会生物技术委员会关于原研生物制剂与生物类似药在免疫介导性风湿病中互换性的立场声明

2026-01-300
PRE
Brazilian Society of Rheumatology-2025 recommendations on vaccination in immune-mediated rheumatic diseases

巴西风湿病学学会-2025年关于免疫介导性风湿病疫苗接种的建议

2026-01-230
PRE
Comparison of the immunogenicity and safety among COVID-19 vaccines ChadOx-1, CoronaVac and BNT162b2 in systemic lupus erythematosus (SLE) patients: a prospective cohort

比较COVID-19疫苗ChadOx-1、CoronaVac和BNT162b2在系统性红斑狼疮(SLE)患者中的免疫原性和安全性:一项前瞻性队列研究

2025-11-220
PRE
Reply to the letter on Brazilian guidelines for the management of tuberculosis infection in immune-mediated inflammatory diseases: is retesting in latent tuberculosis screening appropriate and safe?

回复关于巴西免疫介导性炎症疾病中结核感染管理指南的信件:在潜伏性结核筛查中重新检测是否适当和安全?

2025-11-190
OA
Immunogenicity and safety to SARS-Cov-2 vaccination in patients with systemic vasculitis

系统性血管炎患者对SARS-Cov-2疫苗接种的免疫原性和安全性

2025-11-180
OAAI
Primary and Booster COVID-19 Vaccination in Patients with Sjögren’s Disease: Data from the Longitudinal SAFER Cohort Study

原发性及加强剂COVID-19疫苗接种在舍格伦综合征患者中的效果:纵向SAFER队列研究数据

2025-11-150
OAAI
Brazilian Registry of Sjogren's Disease (BRAS): a full picture of Sjogren's disease in Brazil
2025-10-270
PRE
Impact of SARS-CoV-2 Vaccination on Disease Activity and Severity of COVID-19 Infection in Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study

系统性红斑狼疮患者中SARS-CoV-2疫苗接种对COVID-19感染活动性和严重程度的影响:一项多中心队列研究

2025-10-210
OAAI
Prevalence of sarcopenia and its association with clinical features and health-related quality of life in Brazilian women with systemic lupus erythematosus

巴西系统性红斑狼疮女性中肌少症的患病率及其与临床特征和健康相关生活质量的关系

2025-04-280
OA
Immunogenicity of SARS-CoV-2 Vaccination Schedules Including a Booster Dose in Patients with Systemic Lupus Erythematosus: Data from a Prospective Multicenter Study

系统性红斑狼疮患者SARS-CoV-2疫苗接种计划包括加强剂量的免疫原性: 来自前瞻性多中心研究的数据

2025-01-270
OAAI
Immunogenicity and Safety According to Immunosuppressive Drugs and Different COVID-19 Vaccine Platforms in Immune-Mediated Disease: Data from SAFER Cohort
2024-12-030
OAAI
Predictors of Hospitalization in Breakthrough COVID-19 among Fully Vaccinated Individuals with Immune-Mediated Rheumatic Diseases: Data from SAFER-Study
2024-09-091
OAAI
IMMUNOGENICITY AND SAFETY OF COVID19 VACCINES IN PATIENTS WITH JUVENILE AUTOIMMUNE DISEASES: DATA FROM SAFER STUDY

COVID-19疫苗在青少年自身免疫性疾病患者中的免疫原性和安全性:SAFER研究数据

2024-06-010
PRE
MUSCLE ULTRASOUND COULD PROVIDE PREDICTIVE INFORMATION IN RHEUMATOID ARTHRITIS PATIENTS: A 1-YEAR PROSPECTIVE COHORT STUDY

肌肉超声可能为类风湿关节炎患者提供预测信息:一项为期1年的前瞻性队列研究

2024-06-010
PRE
BIVALENT MRNA COVID-19 VACCINE BOOSTER DOES NOT INCREASE THE RISK OF FLARE IN RHEUMATOID ARTHRITIS PATIENTS UNDER REAL LIFE SETTING - DATA FROM SAFER STUDY

双价mRNA COVID-19疫苗加强针在真实世界环境中不会增加类风湿关节炎患者的疾病复发风险——SAFER研究数据

2024-06-010
PRE
THE EFFECT OF COMBINATIONS OF CONVENTIONAL SYNTHETIC DMARDs ON THE SAFETY AND TREATMENT RETENTION OF BIOLOGIC AGENTS OR JAK INHIBITORS IN RHEUMATOID ARTHRITIS

传统合成DMARDs组合对生物制剂或JAK抑制剂在类风湿关节炎中安全性与治疗保留率的影响

2024-06-010
PRE
FACTORS ASSOCIATED WITH VACCINE RESPONSE AFTER COVID VACCINE BOOSTER IN PATIENTS WITH AUTOIMMUNE DISEASES: DATA FROM MULTICENTRIC PROSPECTIVE PHASE IV SAFER STUDY

与自身免疫性疾病患者COVID疫苗加强针后疫苗应答相关的因素:来自多中心前瞻性IV期SAFER研究的数据

2024-06-010
PRE